Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Implantation of acellular biomimetic scaffolds with proangiogenic motifs may have exciting clinical utility for the treatment of ischemic pathologies such as myocardial infarction. Although direct delivery of angiogenic proteins is a possible treatment option, smaller synthetic peptide-based nanostructured alternatives are being investigated due to favorable factors, such as sustained efficacy and high-density epitope presentation of functional moieties. These peptides may be implanted in vivo at the site of ischemia, bypassing the first-pass metabolism and enabling long-term retention and sustained efficacy. Mimics of angiogenic proteins show tremendous potential for clinical use. We discuss possible approaches to integrate the functionality of such angiogenic peptide mimics into self-assembled peptide scaffolds for application in functional tissue regeneration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.biomac.8b01137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CIB1 and platelet integrin αIIbβ3: Molecular mechanisms, disruption strategies and antithrombotic opportunities.
Thromb Res
September 2025
Departamento de Química and Institute for advanced research in chemical Science (IAdChem), Facultad de Ciencias, Módulo 13, Universidad Autónoma de Madrid, 28049, Madrid, Spain.
Platelet integrin αIIbβ3 is the final common effector of arterial thrombosis: it switches from a low-affinity to a high-affinity state, binds fibrinogen, and initiates the outside-in signals that stabilize a growing clot. Calcium- and integrin-binding protein 1 (CIB1) emerged as the first endogenous partner of the αIIb cytoplasmic tail and is now recognized as a dual-role adaptor. At rest, Ca-free CIB1 tethers the inner membrane clasp and restrains premature integrin activation; after ligand engagement, Ca-bound CIB1 docks onto αIIb, recruits focal-adhesion kinase and amplifies Src-dependent cytoskeletal remodeling.
View Article and Find Full Text PDFSelf-Assembled Nanoparticle Vaccines Elicit Robust Protective Immune Responses against Type O Foot-and-Mouth Disease Virus Infection.
ACS Nano
September 2025
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan 430070, Hubei, China.
Foot-and-mouth disease virus (FMDV), a critical pathogen in the global livestock industry, has long been a focal point of international disease control strategies. This study developed a nanoparticle-based FMDV vaccine platform. We fused the FMDV immunodominant epitope (VP1-G-H-loop) and T-cell epitope (T) with the nanoparticle scaffold (LS), efficiently producing the T-LS-LOOP nanoparticle vaccine using the prokaryotic expression system (BL21).
View Article and Find Full Text PDFComposite Scaffolds of Decellularized Placenta/PRP Enhance the Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells Into Insulin-Producing Cells In Vitro.
J Biomed Mater Res B Appl Biomater
September 2025
Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
In the current in vitro experiment, we fabricated and characterized placenta/platelet-rich plasma (PL/Pt) composite scaffolds and evaluated their effect on differentiating adipose stem cells (ASCs) into insulin-producing cells (IPCs) in vitro. The human placenta (PL) was decellularized (dPL), characterized, and digested in pepsin. PRP was extracted using a two-step centrifugation process and then freeze-dried.
View Article and Find Full Text PDFA concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT.
Bioorg Med Chem Lett
September 2025
Department of Radiology, The University of Chicago, Chicago, IL 60637, United States. Electronic address:
Murine double minute 2 (MDM2, also known as human double minute 2 or HDM2) is a negative regulator of the tumor suppressor protein p53 and is overexpressed in many cancers. Over the past two decades, substantial progress has been made in developing inhibitors of the MDM2-p53 interaction, thereby allowing the p53 protein to exert antitumor effects through cell apoptosis and cycle arrest. While there are currently no FDA-approved MDM2 inhibitors available, several small molecule MDM2 inhibitors and a stapled peptide inhibitor of the MDM2-p53 interaction are in clinical development.
View Article and Find Full Text PDFDesign of peptide-based PAC1 antagonists combining molecular dynamics simulations and a biologically relevant cell-based assay.
Biochem Pharmacol
September 2025
Section on Molecular Neuroscience, NIMH-IRP, Bethesda, MD, USA. Electronic address:
The PACAP receptor PAC1 is a G-coupled family B1 GPCR for which the highest-affinity endogenous peptide ligands are the pituitary adenylate cyclase-activating peptides PACAP38 and PACAP27, and whose most abundant endogenous ligand is PACAP38. PACAP action at PAC1 is implicated in neuropsychiatric disorders, atherosclerosis, pain chronification, and protection from neurodegeneration and ischemia. As PACAP also interacts with two related receptors, VPAC1 and VPAC2, highly selective ligands, both agonists and antagonists, for PAC1 have been sought.
View Article and Find Full Text PDF